Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Filings indexed 3,411 across all filing types
Latest filing 2025-03-31 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Imfinzi approved in the US for bladder cancer
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 7951C' and is dated March 31, 2025. It announces a significant regulatory event: the FDA approval of AstraZeneca's drug Imfinzi for muscle-invasive bladder cancer, citing Phase III trial results. The text concludes with standard disclaimers and contact information related to 'RNS, the news service of the London Stock Exchange' and states that RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider. This structure is characteristic of a general regulatory news announcement disseminated via the London Stock Exchange's RNS system, rather than a comprehensive financial report (like 10-K or IR) or a specific management/governance filing. Since it is a broad regulatory announcement that doesn't fit the specific categories like DIV, ER, or MANG, the most appropriate fallback is Regulatory Filings (RNS).
2025-03-31 English
AZN INVESTS $2.5BN IN BEIJING R&D & MANUFACTURING
Regulatory Filings
2025-03-21 English
AZN invests $2.5bn in Beijing R&D & manufacturing
Regulatory Filings Classification · 98% confidence The document is an official announcement from AstraZeneca regarding a $2.5 billion investment in a new R&D centre and strategic partnerships in Beijing. It is distributed via the London Stock Exchange's RNS (Regulatory News Service). Since it describes a specific corporate development/strategic investment rather than a financial report, dividend, or management change, and does not fit into the more specific categories like M&A or Capital/Financing (as it is an operational investment/partnership announcement), it falls under the general regulatory filing category.
2025-03-21 English
ENEBOPARATIDE PHASE III TRIAL MET PRIMARY ENDPOINT
Regulatory Filings
2025-03-17 English
IMFINZI APPROVED IN EU FOR LIMITED-STAGE SCLC
Regulatory Filings
2025-03-17 English
ASTRAZENECA TO ACQUIRE ESOBIOTEC
Regulatory Filings
2025-03-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.